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RESUMO  
 
As doenças cardiovasculares (DCVs) são uma das principais causas de morte mundialmente e um 
dos factores que está na sua origem é a hipercolesterolémia. 
A hipercolesterolémia pode ter uma base genética (hipercolesterolémia familiar, HF) e não 
genética (hipercolesterolémia clínica, HC), sendo a primeira muito mais severa, originando 
aterosclerose prematura. 
Se por um lado a função patofisiológica da homocisteína (Hcy) na DCV é ainda controversa, por 
outro, a S e N-homocisteinilação de proteínas oferece um novo paradigma a ser considerado na 
patogénese vascular da hipercolesterolémia. 
Neste sentido, o presente estudo ambiciona revelar novos conceitos sobre a ligação de Hcy a 
proteínas, na HC e HF. 
Foram incluídos no estudo 187 indivíduos: 65 normolipidémicos e 122 hipercolesterolémicos. 
As fracções de Hcy total (tHcy) e livre (fHcy) foram quantificadas em amostras de soro após 
validação de um método de HPLC-FD, para avaliar a S-homocisteinilação. A actividade de lactonase 
(LACase) da enzima paraoxonase-1 (PON1) foi quantificada por um ensaio colorimétrico para avaliar 
a N-homocisteinilação. 
Os níveis de tHcy não diferem entre grupos. Não obstante, a fracção fHcy diminui nos grupos 
hipercolesterolémicos, com maior evidência para a população HF. Consequentemente, parece haver 
um aumento de S-homocisteinilação, independentemente da terapia de redução lipídica (TRL). 
Também a actividade LACase é mais baixa neste grupo, mesmo com TRL, por isso, o risco de N-
homocisteinilação parece ser maior. 
Além disso, a diminuição dos rácios LACase/ApoA1 e LACase/HDL na população HF mostra que 
a lipoproteína de alta densidade (HDL) está disfuncional nesta população apesar da concentração ser 
normal. 
Os resultados suportam a hipótese de que a função patofisiológica da Hcy na hipercolesterolémia 
pode residir na sua capacidade de fazer modificações pós-traducionais em proteínas. Este fenómeno 
é particularmente evidente na condição de HF. No futuro será interessante identificar quais as 
proteínas-alvo envolvidas na progressão da patologia vascular. 
 
 
 
PALAVRAS-CHAVE: Hipercolesterolémia; Doença cardiovascular; Homocisteinilação de proteínas; 
Paraoxonase-1; Actividade lactonase. 
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ABSTRACT  
 
Cardiovascular diseases (CVDs) are one of the leading causes of death and disability worldwide 
and one of its underlying causes is hypercholesterolemia. Hypercholesterolemia can have genetic 
(familial hypercholesterolemia, FH) and non-genetic causes (clinical hypercholesterolemia, CH), the 
first much more severe, with occurrence of premature atherosclerosis. 
While the pathophysiological role of homocysteine (Hcy) on CVD is still controversial, molecular 
targeting of protein by S and N-homocysteinylation offers a new paradigm to be considered in the 
vascular pathogenesis of hypercholesterolemia.  
On this regard, the present study aims to give new insights on protein targeting by Hcy in both CH 
and FH conditions.  
A total of 187 subjects were included: 65 normolipidemic and 122 hypercholesterolemic. 
Total (tHcy) and free (fHcy) fractions were quantified in serum samples after validation of an HPLC-
FD method, to assess S-homocysteinylation. Also, the lactonase (LACase) activity of paraoxonase-1 
(PON1) was quantified by a colorimetric assay, as a surrogate of N-homocysteinylation. 
tHcy does not differ among groups. Nevertheless, fHcy declines in the hypercholesterolemic 
groups, with more evidence to the FH population. Consequently, there seems to be an increase of S-
homocysteinylation, regardless of lipid lowering therapy (LLT). Also, despite of LLT use, LACase 
activity is lower in FH, thus the risk for protein N-homocysteinylation seems to be higher. 
Moreover, the decrease in LACase/ApoA1 and LACase/HDL ratios in FH, shows that HDL is 
dysfunctional in this population, despite its normal concentration values.  
Data supports that the pathophysiological role of Hcy on hypercholesterolemia may reside in its 
ability to post-translationally modify proteins. This role is particularly evident in FH condition. 
In the future, it will be interesting to identify which target proteins are modified and thus involved in 
vascular pathology progression. 
 
 
 
 
KEYWORDS: Hypercholesterolemia; Cardiovascular disease; Protein homocysteinylation; 
Paraoxonase-1; Lactonase activity. 
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1.1 Cardiovascular disease’s burden in the XXI century 
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels that 
include coronary heart disease (CHD), cerebrovascular and congenital heart disease, among others 
(WHO, 2015).  
According to the World Health Organization (WHO), approximately 17 million people die of CVD 
every year, particularly heart attacks and strokes. This number is increasing each year and it is 
expected to reach 23.3 million people until 2030 (WHO, 2015). CVDs occur almost equally in men and 
women. Although heart attacks and strokes are major killers in all parts of the world, 80% of premature 
deaths from these causes could be avoided by controlling the main risk factors: tobacco, unhealthy 
diet and physical inactivity (WHO, 2015). CVD is the leading cause of death in developing and 
developed countries, Portugal included (Figure 1.1) (WHO, 2015). It causes more than half of all 
deaths across the European Region and it represents 46 times the number of deaths and 11 times the 
disease burden caused by acquired immunodeficiency syndrome (AIDS), tuberculosis and malaria 
combined, in Europe (WHO, 2015). 
 
Figure 1.1 Percentage of deaths caused by cardiovascular diseases in Portugal (adapted from 
WHO, 2014). NCDs: Non-communicable diseases 
 
1.2 Hypercholesterolemia pathophysiology 
Hypercholesterolemia is characterized by high serum levels of cholesterol, and its deposition in the 
artery wall leads to atherosclerosis, the underlying cause of CVD (Çı̇ftçı̇ et al., 2015). 
Hypercholesterolemia can have genetic (familial hypercholesterolemia, FH) and non-genetic causes 
(clinical hypercholesterolemia, CH), being the first much more severe, with occurrence of premature 
atherosclerosis (Marais, 2004). 
FH is a monogenetic condition transmitted through an autosomal dominant pattern with an 
estimated prevalence of 1 in 500 in the heterozygous (HeFH) form in most populations (Hutter et al., 
2004) and is characterized by permanent high levels of circulating low-density lipoprotein (LDL) 
Cardiovascular	
diseases			32%
Cancer	28%Chronic	respiratory	
diseases	6%
Diabetes	5%
Other	NCDs
15%
Communicable,	 	
maternal,	perinatal	
and	nutritional	
conditions
10%
Injuries
4%
Proportional mortality (% of total deaths, all ages, both sexes)
Total deaths:	97,000
4 
 
particles (Medeiros et al., 2014). The homozygous form of the disease is very rare (1 in 1 million) and 
very severe with onset in the first two years of life (Marais, 2004). 
There are currently three systems at use for a clinical diagnostic of FH after which people are 
selected for genetic testing. The diagnostic criteria used by the National Institute of Health Doutor 
Ricardo Jorge (INSA) for diagnosing a person with HeFH was adapted from the Simon Broome Heart 
Register Group in the UK (Bourbon and Rato, 2006; Scientific Steering Committee, 1999) and it 
reflects on LDL and total cholesterol (TC) levels above 190 mg/dL and 290 mg/dL, respectively, as 
well as family history of hypercholesterolemia and premature CVD (Annex I). Usually, triglyceride 
levels are normal. If not treated, 50% of male before 50 and 30% of female before 60 years old will 
likely develop CHD (Kim and Han, 2013). Sometimes there are also physical symptoms that result 
from cholesterol deposition within macrophages on extra vascular tissues (Bourbon and Rato, 2006; 
Kim and Han, 2013) and facilitate medical diagnosis, for example, xanthomas in the Achilles tendon, 
knees or finger tendons, which appear irregular and thickened (Bourbon and Rato, 2006; Marais, 
2004), xanthelasmas which are cholesterol deposits on the eyelids and arcus cornealis that appears 
from cholesterol infiltration around the cornea (Kim and Han, 2013). 
In 1980, Goldstein and Brown – Nobel prize recipients for their research on cholesterol metabolism 
– discovered the molecular basis of the disease which is the mutations occurring on LDL receptor 
gene (LDLR) causing half or total defective LDL receptors (LDLR) at the surface of several cell types, 
including hepatocytes (Avis et al., 2007; Bourbon and Rato, 2006). The studies that followed over the 
years, contributed for the discovery of two other genes connected to the FH phenotype: apolipoprotein 
B (APOB) and proprotein convertase subtilisin/kexin type 9 (PCSK9) (Bourbon and Rato, 2006). 
LDLR mutation is found in most FH cases and more than 1000 different mutations have been 
described (Kim and Han, 2013; Medeiros et al., 2010). The fact that these malfunctioning receptors 
can’t make the uptake of LDL particles into the cells, particularly the liver, for processing and 
degradation, leads to the accumulation on vessel walls initiating the atherogenic process and 
premature CVD (Avis et al., 2007; Medeiros et al., 2014). 
ApoB is an apolipoprotein associated with LDL and the only particle connecting LDL to its receptor 
on the liver. When the mutation occurs on the APOB gene, the apolipoprotein formed cannot bind 
LDL, hence, the clinical phenotype is similar to the ones in LDLR mutations (Austin et al., 2004; 
Bourbon and Rato, 2006). 
The last gene found to be associated with FH was PCSK9 in 2004 (Bourbon and Rato, 2006). 
PCSK9 codes the information for a serine protease that helps regulate the amount of cholesterol in the 
bloodstream by controlling the number of LDL receptors at the hepatocytes surface (Maxwell et al., 
2005). Apparently, the protein does its function by breaking down the receptors before they reach the 
cell’s surface, interfering with their recycling (Horton et al., 2007). The mutation changes a single 
amino acid and provokes a gain of function of the protein that exacerbates its activity, i.e., the 
degradation rate of the receptors is higher (Cameron et al., 2006). Fewer receptors implicate higher 
LDL levels on the bloodstream.  
A schematic representation of FH onset and its physiological implications can be seen in Figure 
1.2. 
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Figure 1.2 Pathophysiology of familial hypercholesterolemia (adapted from Nordestgaard et al., 
2013). ApoB: Apolipoprotein B; LDL: Low-density lipoprotein; LDLR: Low-density lipoprotein receptor; PCSK9: 
Proprotein convertase subtilisin/kexin type 9. 
 
Besides the defects on LDL receptors, patients with HeFH develop a damaged flow-mediated 
dilatation of the brachial artery (de Jongh et al., 2002) and an increased intima media thickness of the 
carotid artery (Wiegman et al., 2004) that result in functional and morphological changes on the blood 
vessels since infancy (Avis et al., 2007). In 2005, Sankatsing and co-authors showed that these 
abnormalities are representative markers of atherosclerotic vascular disease (Sankatsing et al., 2005), 
so it is important that treatment starts at a young age. 
 
1.3 Protein homocysteinylation and paraoxonase-1 detoxification 
Homocysteine (Hcy) is part of a group of amino acids that possesses a thiol group (-SH), called 
aminothiols, where cysteine (Cys), cysteinylglicine (Cys-Gly) glutathione (GSH) and N-acetilcysteine 
(NAC) are also members.  
Hcy can enter two metabolic pathways. It is either converted by transsulfuration to cystathionine 
and then into Cys or it is remethylated to methionine (Met). The first process requires the enzyme 
Cystathionine ß-synthase (CBS) and vitamin B6 as a cofactor; in the second, vitamin B12 and 5,10-
methyl-tetrahydrofolate serve as cofactors for methionine synthase (MS) (Hankey and Eikelboom, 
1999; Jakubowski, 2006).  
The only source of Hcy in the human body is through protein ingestion (Yilmaz, 2012). Normal total 
Hcy (tHcy) levels in the human body range from 5 to 15 µM and higher values are classified as 
moderate (16-30 µM), intermediate (31-100 µM) and severe (>100 µM) hyperhomocysteinemia (HHcy) 
(Hankey and Eikelboom, 1999). The term “total Hcy” refers to the pool of all Hcy fractions in the blood 
(Yilmaz, 2012).  
HHcy is an established risk factor for the onset and development of atherosclerosis in susceptible 
populations (Olszewski and Mccully, 1991). High levels of fasting tHcy are associated with coronary 
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atherosclerosis in patients affected by FH in both males and females (Pisciotta et al., 2005). Every 
increase of 2.5 µM in plasma Hcy may be associated with an increase of stroke risk of about 20% 
(Malinowska et al., 2012). Although severe HHcy is rare, moderate HHcy is a rather frequent factor in 
the general population (Jakubowski, 2008), which increases the vascular risk and the formation of 
homocysteine-thiolactone (HcyTL). For instance, tHcy above 20 µM is associated with a nine-fold 
increase of the myocardial infarction and stroke risk (Malinowska et al., 2012). 
Despite these observations, pathophysiological role of Hcy on CVD is still controversial. On one 
hand, tHcy is accepted as an independent risk factor. On the other hand, studies aimed at lowering its 
plasma concentrations showed no significant reduction on cardiovascular risk (Cheng, 2013). This 
might indicate that by monitoring tHcy itself, valuable information might be lost. In fact, 80% of the total 
amount of homocysteine in circulation is bound to proteins (Hankey and Eikelboom, 1999). 
Molecular targeting of proteins by N-homocysteinylation (due to acylation of free amino groups 
mediated by Hcy toxic metabolite, HcyTL) or by S-homocysteinylation (formation of disulphide bonds 
with protein’s Cys residues mediated by Hcy itself) may have a role on the pathogenesis of 
hypercholesterolemia (Malinowska et al., 2012). 
Both N- and S-homocysteinylation have well-established pathophysiological consequences owed 
to protein structure modification, as protein inactivation, cell damage, oxidative stress, activation of 
autoimmune response and enhanced thrombosis (Zinellu et al., 2012) (Table 1.1). 
There are two different types of disulphides in protein structures that have different functional roles: 
one type of disulphides stabilizes proteins by cross-linking their polypeptide chains while others are 
redox reactive and thus may react with free aminothiols, such as Hcy (Jakubowski, 2013). These 
alterations can change the redox balance of proteins (Malinowska et al., 2012) Plasma S-thiolated 
proteins have been detected in healthy humans, in patients with cardiovascular disease and in several 
cell types after oxidant exposure (Zinellu et al., 2006). 
Proteins are N-homocysteinylated at rates proportional to the amount of lysine (Lys) residues 
present, and a physiologic concentration of HcyTL of 10 nM is sufficient to start the process 
(Jakubowski, 2006; Zinellu et al., 2006). N-Hcy-proteins levels in human plasma are several times 
higher than the plasma levels of HcyTL (0-35 nM), varying from 0.1 µM to 13 µM, meaning that most 
HcyTL formed establishes immediate bonds with the amino groups of proteins (Jakubowski, 2006). 
HcyTL formation occurs in all cells tested thus far, including human vascular endothelial cells, 
when Methionyl-tRNA syntethase selects by error Hcy instead of Met in an editing reaction of protein 
synthesis (Jakubowski, 2006; Yilmaz, 2012). This process is favoured when the two other pathways 
are impaired by lack of vitamin B6, B12 and/or folate (B9) intake, by high-Met diet or by genetic 
alterations of enzymes involved in Cys/Met metabolism – CBS, MS and/or methylenetetrahydrofolate 
reductase (Jakubowski, 2006).  
Generally, the percentage of tHcy that binds to proteins as N-Hcy in human plasma of healthy 
individuals is 3–7% (Jakubowski, 2008). Increased total plasma Hcy concentrations lead to increased 
production of HcyTL and N-homocysteinylation which in turn favours the number of -SH sites available 
for S-homocysteinylation (Zinellu et al., 2006). The opposite also happens. Human serum albumin has 
been the most studied N-Hcy-protein. It was noted that the protein disulphide form established 
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between Cys34 residue and a free Cys aminothiol was N-homocysteinylated faster than 
mercaptoalbumin (the form with free reduced Cys34 residue) (Jakubowski, 2006). Lys525 residue of 
albumin is two times more reactive to N-homocysteinylation when the protein is in its disulphide form 
than when Cys34 is reduced, leading to a final product much more susceptible to proteolysis 
(Jakubowski, 2006). 
 
Table 1.1 Cardiovascular consequences of S and N-homocysteinylated proteins. 
S-homocysteinylated 
protein 
Pathogenic role Reference 
Albumin Modification of the intracellular redox potential 
Sengupta et al., 
2001 
ApoB-100 (major 
component of LDL) 
Increase of reactive oxygen species (ROS) 
production and cytotoxicity 
Jakubowski et al., 
2013 
Fibrillin 
Structural changes that lead to protein 
misfolding 
Jakubowski et al., 
2013 
Fibronectin 
Function and fibrin interaction are impaired; pro-
thrombotic effect and vascular occlusion 
Gluschenko and 
Jacobsen, 2007 
Factor Va 
Resistance to inactivation by activated protein C 
– pro-thrombotic tendency 
Lentz et al., 2002; 
Gluschenko and 
Jacobsen, 2007 
Annexin A2 
Decrease of tissue plasminogen activator (t-PA) 
ligation - pro-thrombotic phenotype 
Zinellu et al., 2006 
Transthyretin Potential role on amyloid deposition 
Gluschenko and 
Jacobsen, 2007 
 
N-homocysteinylated 
protein 
Pathogenic role Reference 
Albumin Increasing of oxidative stress and proteolysis Perna et al., 2006 
Fibrinogen 
Impaired fibrinolysis – pro-thrombotic 
tendency 
Sauls et al., 2011 
ApoA1 
Reverse cholesterol transport dysfunction – 
atherosclerosis lesions 
Ishimine et al., 2010 
Insulin Protein aggregation and fibrillation Yousefi et al. 2012 
ApoA1: Apolipoprotein A1; ApoB: Apolipoprotein B 
 
High-density lipoprotein (HDL) and LDL have also been subject of homocysteinylation studies. LDL 
interaction with HcyTL causes aggregation of the lipoprotein and higher uptake by cultured 
macrophages (Zinellu et al., 2006). Ferretti and co-workers theorized that the oxidative stress caused 
by Hcy on human aortic endothelial cells could be explained by the internalization of N-
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homocysteinylated LDL by membrane receptors with intracellular release of Hcy after hydrolytic 
degradation (Ferretti et al., 2004). The authors have also reported that LDL incubation with 100 µM 
HcyTL for two hours causes N-homocysteinylation of ≈10% of apoB-100 Lys residues  (Ferretti et al., 
2004). 
As to HDL, it is the major carrier of hydroperoxides in plasma and that happens as consequence of 
oxidation at inflammation sites and re-entry into circulation or by transfer of oxidized lipids from LDL to 
HDL (Ferretti et al., 2010). An increase in lipid hydroperoxides and other oxidation markers 
destabilizes the lipoprotein structure, facilitating HcyTL access to HDL amino groups (Ferretti et al., 
2010).  
 
HcyTL is detoxified by the lactonase (LACase) activity of Paraoxonase-1 (PON1), an HDL-
associated enzyme, hence avoiding protein N-homocysteinylation and its nefarious effects on the 
organism (Yilmaz, 2012) (Figure 1.3). 
LACase is nowadays considered to be the native function of this enzyme in mammal’s organisms 
(Jakubowski, 2000). It was first proposed by Jakubowski that PON1 evolved to metabolise HcyTL 
(Jakubowski, 2000). Further on, other investigators found that it is also able to hydrolyse other classes 
of endogenous lactones, specifically, aromatic and aliphatic lactones that arise from oxidation of 
polyunsaturated fatty acids (PUFAs) and result in modulation of the local anti-inflammatory response 
(Draganov et al., 2005; Khersonsky and Tawfik, 2005). 5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic 
acid lactone (5-HETEL) and 5,6-dihydroxytrienoic acid-1,5 lactone (5,6-DHETL) are lactones 
originated through one of araquidonic acid (AA) oxidative pathways, the lipoxygenase pathway 
(Draganov and Teiber, 2008). 5-HETEL inhibits platelet neutrophil phospholipase A2, an inflammatory 
mediator that unchains the AA cascade, and cycloxygenase, the enzyme involved in the oxidative 
pathway that originates thromboxane A2 and prostaglandins (Draganov and Teiber, 2008). 5,6-DHETL 
is a potent vasodilator that is rapidly metabolised by PON1 to 5,6-dihydroxyeicosatrienoic acid (5,6-
DHET), though it is not known what the physiological effect of this metabolism in vivo might be 
(Draganov and Teiber, 2008). 5-hydroxy-6-iodo-8,11,14-eicosatrienoic acid δ-lactone (δ-iodolactone) 
inhibits signal transduction pathways that are activated by local growth factors (e.g. epidermal and 
fibroblast) (Draganov and Teiber, 2008). 
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Figure 1.3 Protein targeting by homocysteine and vascular protection conferred by lactonase 
activity (adapted from Dias et al., 2015). 5-HETEL: 5-hydroxy-eicosatetraenoic acid lactone; 5,6-DHETL: 
5,6-dihydroxytrienoic acid-1,5 lactone; δ-iodolactone: 6-Iodo-5-hydroxy-8,11,14-eicosatrienoic trienoic acid δ-
lactone; CBS: Cystathionine ß-synthase; CGL: cystathionine γ-lyase; Cys: Cysteine; Cysta: Cystathionine; ER: 
Endoplasmic reticulum; FOL: Folate; GSH: Glutathione; GSHS: Glutathione synthetase; Hcy: Homocysteine; 
HcyTL: Homocysteine-thiolactone; LACase: Lactonase; Met: Methionine; MS: Methionine synthase; N-Hcy P: N-
homocysteinylated protein; S-Hcy P: S-homocysteinylated protein; SAHase: S-adenosylhomocysteine hydrolase. 
 
Human PON1 is a calcium-dependent glycoprotein, one calcium ion with a structural role and the 
other with a catalytic function, mainly expressed in the liver (Perła-Kaján and Jakubowski, 2012). It 
was firstly classified as an aryldialkylphosphatase (EC 3.1.8.1) and later, it was also designated by 
Aldrige, in 1953, an A-esterase for its ability to hydrolyse organophosphates (Mackness and 
Mackness, 2013). It retains the hydrophobic sequence on the N-terminal region, which allows the link 
with HDL (Draganov et al., 2005; Farid and Horii, 2012). 95% of PON1 content exists on a subclass of 
HDL, HDL3, which is responsible for most of HDL antioxidant capacity and contains also 
apolipoprotein A1 (ApoA1) and clusterin (Farid and Horii, 2012; Gugliucci et al., 2012; Mackness and 
Mackness, 2013). PON1 activity largely depends on its association with apoA1 and phospholipids in 
HDL, although a minor, free form can be found (Gugliucci et al., 2012). 
It is believed to have antiatherogenic and antioxidant properties and a broad substrate specificity 
going from drug metabolism and nerve agents detoxification (sarin and soman) to the metabolism of 
organophosphates (paraoxon, diazoxon), aromatic esters (phenyl acetate) and several classes of 
lactones (HcyTL, PUFA lactones and statins with lactone structure) (Draganov et al., 2005; Perla-
Kaján and Jakubowski, 2012). 
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1.4 Objectives  
General aim 
Molecular targeting of protein by Hcy offers a new paradigm to be considered in the pathogenesis 
of hypercholesterolemia. This work aimed to give new insights on protein targeting by Hcy in 
hypercholesterolemia condition with genetic (familial hypercholesterolemia, FH) and non-genetic 
aetiology (clinical hypercholesterolemia, CH). 
Specific aims 
ü To optimize and validate a method for Hcy fractions quantification; 
ü To compare tHcy and its fractions (fHcy and S-Hcy-P) in normolipidemic, CH and FH patients; 
ü To explore S-protein bound fraction in normolipidemics, CH and FH patients; 
ü To assess N-protein bound fraction through the use of LACase activity as a surrogate; 
ü To ascertain the effect of lipid lowering drugs use in LACase and in tHcy and its fractions, in 
the three populations; 
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2. MATERIALS AND METHODS 
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2.1 Study population and patient’s inclusion 
The Portuguese Familial Hypercholesterolemia Study has been implemented in 1999 at the INSA 
following WHO recommendations for a universal FH screening, in 1998 (WHO, 1998). People with a 
clinical diagnosis of FH have been recruited by clinicians all over the country to perform genetic tests 
to identify a possible mutation (Medeiros et al., 2015). Parallel to this, there is a national study being 
developed at INSA named “eCOR” that was designed to estimate the prevalence of major 
cardiovascular risk factors in the general Portuguese population. 
The eCOR project has so far, a total of 1685 individuals included and approximately 20% are under 
lipid lowering therapy. Randomized samples have been collected from 5 Portuguese sub-regions 
defined for statistic means (North, Centre, Lisboa, Alentejo and Algarve) and stratified by age and sex 
in order to be representative of the Portuguese adult population, aged between 18-79 years old. Data 
collection includes an individual survey, physical examination and clinical history. Serum samples 
were collected after a 12-hour fasting, by venipuncture, in healthcare centres across the country and 
sent to INSA. 
The current work was conducted in accordance with the Declaration of Helsinki. The study protocol 
and database have been approved by the National Institute of Health Ethics Committee and the 
National Data Protection Commission, respectively. Written informed consent was obtained from all 
participants before their inclusion in the study. 
A subgroup has been selected and divided into three groups according to their TC levels to 
quantify LACase activity and Hcy fractions: subjects from the eCOR with normal cholesterol levels; 
patients previously diagnosed with CH and patients diagnosed with FH. Both hypercholesterolemic 
groups were diagnosed at INSA, following Simon Broome criteria (Annex I). Lipid reference values 
adopted in this study were followed according to the guidelines established by the European Society 
of Cardiology for the general population (ESC/EAS, 2011) (Table 2.1). 
 
Table 2.1 Lipid reference values based on ESC guidelines for the management of 
dyslipidemias. 
Parameter  Recommended value (mg/dL) 
Total cholesterol  < 190 
Low-density lipoprotein  <115 
High-density lipoprotein  >40 for men; >50 for women 
Apolipoprotein B  < 120 
Apolipoprotein A1  >120 for men; >140 for women 
Triglycerides  < 150 
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2.2 Homocysteine quantification: total, free and S-homocysteinylated protein fraction 
 
I. RATIONAL 
Like other aminothiols, Hcy exists mostly in the protein-bounded form (70-80%) due to the reactivity 
of its sulfhydryl group (-SH) but it also circulates in the blood in its free oxidized form as homocysteine 
dimers or mixed disulphides (20-30%) and, in less extent, in a free reduced form (1%) (Hankey and 
Eikelboom, 1999). 
Molecular targeting of proteins by Hcy may occur by N-homocysteinylation or by S-
homocysteinylation (Malinowska et al., 2012). 
In most studies and even in clinical routine analysis, the contribution of Hcy to CVD relies on tHcy 
quantification, which gives limited knowledge, hence probably leading to the loss of valuable 
information. In this sense, it would be important to understand the contribution from each Hcy fraction 
in CVD. To achieve this, a high sensibility quantification method is required. High-performance liquid 
chromatography with fluorescence detection (HPLC-FD) allows the detection of free and total Hcy, 
having the advantage of differentiating from other thiols present in the sample (Cys, Cys-Gly, GSH 
and NAC). S-Hcy-protein fraction is extrapolated by subtracting the free to the tHcy concentration 
(Przemysław et al., 2011). By adapting the conceptual idea for fHcy separation from Przemyslaw and 
co-workers and the analytical method described by Nolin and colleagues (Nolin et al., 2007), a new 
method that allowed the quantification of Hcy fractions was optimized. 
Whenever available, the values of tHcy obtained were compared to those obtained in clinical 
setting.  
 
II. STANDARDS PREPARATION FOR THE CALIBRATION CURVE AND QUALITY CONTROL  
Stock solution 
A L-Homocysteine (Sigma-Aldrich) 10mM stock solution was prepared by dissolving the 
appropriate amount of the solid analyte in 1mL of deionized and distilled water.  
 
Standards preparation 
Three calibration curves were prepared for validation purposes.  
The standards for the calibration curve were prepared by successive dilutions of the stock solution 
in phosphate-buffered-saline (PBS) in order to obtain ten different concentrations of L-Homocysteine 
ranging from 0.625 to 50 µM. 
The quality control (QC) samples were prepared from distinct stock solutions by successive 
dilutions in PBS to obtain final concentrations of Hcy of 37.50, 18.75 and 4.375 µM (QC1, QC2, QC3 
respectively). 
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III. METHOD VALIDATION 
The validation criteria were defined according to guidebooks regarding the validation of 
bioanalytical methods (US-FDA, 2001; EMA, 2011). 
 
Linearity of the method: Three calibration curves were prepared from different stock solutions and 
using 10 standards within the concentration range: 0.625 µM (lower limit of quantification, LLOQ) to 50 
µM (higher limit of quantification, HLOQ). 
The calibration curves were plotted by linear regression of the chromatographic peak area 
(mV*min) as function of analytes concentration (µM) to assess the linearity of the method. Also, the 
slopes and Y-intercept (Y0) of the curves where compared in order to access reproducibility. The 
average back-calculated concentrations were also assessed. 
 
Lower limit of quantification: The LLOQ for Hcy was established at 0.625 µM. In order to validate 
the LLOQ, five runs of this standard were analysed for accuracy and inter-assay precision studies. 
 
Accuracy: Accuracy was defined as the closeness to the theoretical concentration of the QC and 
LLOQ samples. Mean concentration of each QC sample analysed should be within 100±15% of the 
theoretical concentration, except for LLOQ, where 100±20% is acceptable. This parameter was 
calculated using the equation 1. 
 
 
 
Inter-assay precision: Inter-assay precision was assessed by the coefficient of variation (CV) 
obtained from the analysis of QC samples in five runs on different days. The CV of QC should not 
exceed 15%, except for LLOQ for which a 20% variation is acceptable.  
 
Stability: To understand the stability of the main solutions used in this protocol, standards with 
Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and 7-fluorobenzofurazan-4-sulfonic acid 
ammonium salt (SBD-F) were frozen at -80 ºC, overnight and analysed on the next day. Stock-
solutions were also submitted to three freeze-thaw cycles. 
The stability of Hcy was also tested on two separate 50 µM standards after being submitted to two 
different conditions: a) -20 ºC and b) 4 ºC, both overnight. 
 
Selectivity and interference: Interference with other endogenous compounds (Cys, Cys-Gly, GSH 
and NAC) was tested. 
 
Carryover: Sample carryover was evaluated by inserting vials of methanol after every five samples. 
 
 
Accuracy (%) = ___________________ 
Obtained concentration 
Exact concentration 
x 100                             (1) 
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IV. STANDARD OPERATING PROCEDURE 
Sample preparation: The method herein described allows the quantification of tHcy and was 
adapted from a method previously developed by Nolin and colleagues (Nolin et al., 2007). Briefly, the 
analytes present in 50 µL of serum samples were first reduced with 5 µL of TCEP (100g/L, Sigma-
Aldrich) and incubated at room temperature (RT) for 30 minutes. After that, proteins were precipitated 
with 45 µL of trichloroacetic acid solution (TCA, 100 g/L) (Roth), containing 1.0 mM of 
ethylenediaminetetra-acetic acid (EDTA, Sigma-Aldrich). The resulting mix was centrifuged, the pellet 
discarded and a volume of 25 µL of the supernatant was collected and added to a new tube containing 
5 µL of 1.55 M sodium hydroxide (NaOH, VWR), 62.5 µL of 0.125 M sodium tetraborate buffer (pH 9.5, 
Sigma-Aldrich) with 4.0 mM EDTA and 25 µL of SBD-F (1 g/L, Sigma-Aldrich) in borate buffer (0.125 
M with 4.0 mM EDTA). Samples were vortexed and incubated in the dark, at 60 ºC during 1 hour, for 
derivatization. A final volume of 30 µL of the derivatized solution was transferred to microvials and 
placed in the refrigerated autosampler (8 ºC). A 10 µL aliquot was injected into the HPLC system for 
analysis. 
The main procedure steps order was changed for the fHcy fraction extraction, based on 
Przemyslaw methodological concept (Przemysław et al., 2011): first precipitation and removal of 
proteins, and then reduction and derivatization of the supernatant containing the free fraction (Figure 
2.1). 
 
Equipment and chromatographic conditions: HPLC analysis was performed on a Shimadzu system 
(LC-10AD VP) using a reversed-phase C18 LiChroCART 250-4 column (LiChrospher 100 RP-18, 
5µm, VWR) at 29 ºC. Detector was set at excitation and emission wavelengths of 385 and 515 nm, 
respectively. Mobile phase consisted of acetate buffer 0.1 M (pH 4.5, VWR) and methanol (VWR) 
[99:1 (v/v)]. The analytes were separated in an isocratic elution for 20 min at a flow rate of 0.8 mL/min. 
 
 
Figure 2.1 Quantification of total and free homocysteine fraction in serum. 
HPLC-FD: High performance liquid chromatography with fluorescence detection; SBD-F: 7-fluorobenzofurazan-4-
sulfonic acid ammonium salt; TCA: Trichloroacetic acid; TCEP: Tris(2-carboxyethyl)phosphine hydrochloride. 
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2.3. PON1 lactonase activity assessment 
 
I. RATIONAL 
LACase activity is still the least studied PON1 activity, possibly because it was the last PON1 
activity to be discovered and because previous methods have disadvantages that hamper a practical 
clinical application (Billecke et al., 2000; Gaidukov and Tawfik, 2005; Rock et al., 2008). On the other 
hand, it is also the one that raises most interest because of increasing evidence that it is the 
endogenous PON1 activity. Over the years, different authors came to the conclusion that PON’s family 
has a high affinity for lactones so it is nowadays proposed that the native function of PON1 is the 
metabolism of endogenous lactones, namely HcyTL and other arisen from oxidation of 
polyunsaturated fatty acids (PUFAs) (Draganov et al., 2005; Jakubowski, 2000; Khersonsky and 
Tawfik, 2005). This activity is responsible for HcyTL detoxification converting it back to Hcy, which can 
then enter Met and Cys metabolism, hence avoiding HcyTL deleterious effects (Yilmaz, 2012). 
Therefore, LACase activity might be a surrogate of protein N-homocysteinylation. 
The LACase method is based on the stoichiometric production of 3-(o-hydroxyphenyl) propionic 
acid (o-HPPA) resulting from the hydrolytic reaction of the substrate dihydrocoumarin (DHC) (Figure 
2.3). This reaction is monitored spectrophotometrically at 405 nm, following the colour change of the 
pH indicator phenol red (from red to yellow). This method was developed and validated at 
Translational Pharmacology lab (Dias et al., submitted). 
 
II. STANDARDS PREPARATION FOR THE CALIBRATION CURVE 
The stock solutions were prepared by adding the appropriate amount of o-HPPA (Sigma-Aldrich) to 
freshly prepared HEPES buffer (2.0 mM, pH 8.0) (Roth), containing calcium chloride (CaCl2, 1.0 mM) 
(BDH Chemicals Ltd Pool England) and 0.005% albumin from bovine serum (BSA, Roth). Six standard 
samples were prepared for the calibration curve by diluting the stock solutions in physiological serum 
(PS). For correction of the non-enzymatic hydrolysis of o-HPPA, a blank sample was prepared using 
PS and HEPES buffer. 
The accuracy and precision of two QC concentrations (QC1 - 4.92 mM and QC2 - 6.55 mM of o-
HPPA), as well as the LLOQ (1.29 mM of o-HPPA) and the HLOQ (10.24 mM of o-HPPA) were 
evaluated using a previously defined criterion (Dias et al., 2014). 
 
III. STANDARD OPERATING PROCEDURE  
LACase activity was assayed by measuring the extent of the hydrolysis of DHC, using a 
spectrophotometric method adapted to a 96-well microplate (Figure 2.3). Briefly, serum samples were 
diluted in the proportion of 1:5 in PS and incubated during 10 minutes, at 37 °C, as well as the 
previous prepared standards. Then, 190 µl of freshly prepared HEPES buffer (2.0 mM, at pH 8.0) 
containing CaCl2 (1.0 mM), BSA (0.005%), phenol red (106 µM, Fluka) and DHC (1.0 mM, Sigma-
Aldrich) were added per well. After 1 minute of incubation at RT, the absorbance was measured at 
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405 nm on a microplate reader (Biotrack II plate reader, Amersham Biosciences). The activity was 
directly obtained from the calibration curve and expressed as kU/L, which is the amount of enzyme 
producing 1 mM of o-HPPA per minute. As DHC is toxic by inhalation or skin contact substrate (Ceron 
et al., 2014), proper clothing was used.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Quantification of lactonase activity in serum (N-Homocysteinylation surrogate) 
(adapted from Dias et al., 2015).   DHC: dihydrocoumarin; LACase: Lactonase activity; o-HPPA: 3-(o-
hydroxyphenyl) propionic acid; PS: physiological serum; RT: Room temperature. 
 
2.4 Statistical analysis 
Statistical analysis was performed using GraphPad Prism® version 6.0 (GraphPad Software Inc., 
CA). Data was expressed as median [interquartile range, IQR] or frequencies (%), whenever 
applicable. Normality of groups was tested using D’Agostino & Pearson and Shapiro-Wilk test. Chi-
Square test was used to assess data independence. Correlations between parameters were explored 
using Pearson or Spearman’s rank correlation test according to the normality of groups. Comparisons 
between groups were performed using One-way ANOVA or Unpaired t test for normal distributions 
and Kruskal-Wallis or Mann-Whitney U for groups that did not pass the normality test. Values of 
p<0.05 were considered significant. Comparisons with more than two variables were performed using 
Two-way ANOVA test. The F-test was used to explore differences between the slopes and the 
elevations of the calibration curves in the validation of the Hcy method. Variability among data was 
expressed in variation coefficient (CV), expressed as %. 
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3. RESULTS  
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3.1 Development and validation of a homocysteine quantification method 
I. LINEARITY OF THE METHOD 
The linear regression model showed to be the most suitable for fitting a function to the points 
obtained (p value of Run Tests>0.05 and deviation from linearity non significant). There were no 
differences between the slopes and the elevations of the calibration curves (p value of F tests <0.001). 
The correlation coefficient, r2, was higher than 0.999, which is a good indicator of adjustment of all 
calibration curves. The 95% confidence interval for the Y-intercept when X=0 contained zero. The 
average back-calculated concentrations obtained were close to the expected theoretical values at 
each tested concentration and presented differences lower than 14%.	
	
 
 
 
 
 
 
 
	
 
 
 
 
Figure 3.1 Homocysteine calibration curve. m= 19750±84; y(0)= -583±1817. 
 
 
II. LOWER LIMIT OF QUANTIFICATION 
The LLOQ for Hcy was 0.625 µM. The accuracy and inter-assay precision results are presented in 
(Table 3.1). 
 
III. ACCURACY  
The accuracy values obtained for QC1, QC2 and QC3 ranged between 96% and 98% (Table 3.1). 
 
IV. INTER-ASSAY PRECISION 
The inter-assay precision for all samples evaluated was higher than 94% (Table 3.1). 
 
10 
5 
15 
0 
22 
 
Table 3.1 Accuracy and inter-assay precision frequencies for the LLOQ and QC samples of 
homocysteine quantification method. 
LLOQ: lower limit of quantification; QC1: quality control 1; QC2: quality control 2; QC3: quality control 3. 
 
V. STABILITY 
Stability performance showed no interference for using SBD-F and TCEP defrost one time 
(Kruskal-Wallis test). 
Three freeze–thaw cycles had no effect on the stability of tHcy present in the stock-solutions. 
Hcy standards can be maintained overnight at 4 ºC and -20ºC (Kruskal-Wallis test). 
 
VI. SELECTIVITY AND INTERFERENCE 
Hcy retention time was not affected by the presence of other analytes in all standards tested 
(Figure 3.2).  
 
 
 
 
 
 
 
 
Figure 3.2 Representative chromatogram of a standard sample with 50 µM of homocysteine.  
Legend: A – Cysteine peak (5.5 min); B – Homocysteine peak (7.8 min); C – Cys-Gly (8.7 min); D 
– GSH (12.5 min); E – NAC peak (17 min). 
 
 
 
 
 
Standard (µM) Accuracy (%) Inter-assay precision (%) 
LLOQ (0.625) 93 94 
QC3 (4.357) 98 98 
QC2 (18.750) 98 97 
QC1 (37.500) 96 97 
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A chromatogram from a patient sample is shown for comparison effects (Figure 3.3). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Representative chromatogram of a patient sample.  
Legend: B – Homocysteine peak (7.9 min). 
 
VII. CARRYOVER 
There was no evidence for carryover phenomenon.  
 
As a further validation step of the method, tHcy concentrations herein obtained were compared 
with Hcy values provided by the INSA lab, whenever available (Figure 3.4). 
 
 
Figure 3.4 Comparison between serum total homocysteine concentration measured at INSA 
laboratory and the concentration measured at the Translational Pharmacology laboratory. 
(Spearman r=0.892, p<0.001). 
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3.2 Anthropometric and clinical data of the included patients  
A total of 187 individuals (53% men) were included in the study: The normolipidemic group (TC 
<190 mg/dL) included 65 subjects; the clinical hypercholesterolemia group (CH) was composed by 76 
patients and familial hypercholesterolemia group (FH) by 46 patients.  
The characterization of the studied population is presented on Table 3.2. No sex (Chi-square test) 
or age (Kruskal-Wallis test with Dunn’s multiple comparison test) differences were found between 
groups. 
 
Table 3.2 Anthropometric and clinical data. 
aData is presented in number, % or Median [IQR]; bChi-square test. CH: Clinical hypercholesterolemic; FH: 
Familial hypercholesterolemic; LLT: under lipid lowering therapy; n: number of subjects. 
 
The number of patients on lipid lowering therapy (LLT) varied significantly among groups, reaching 
approximately half of the CH patients and almost 75% of the FH population (Chi-square test, p<0.001). 
Table 3.3 describes the number of patients under the different LLT regimens. 
 
Table 3.3 Lipid lowering therapy use by hypercholesterolemic population. 
aData is presented in number. CH: Clinical hypercholesterolemic; FH: Familial hypercholesterolemic; n: number of 
subjects. 
 
Parameter (Unit)a Normolipidemia CH FH p valueb 
n 65 76 46  
Men (%) 49 62 46 ns 
Age (years) 44 [39-50] 44 [36-57] 43 [35-50] ns 
LLT (%) 0 47 74 <0.001 
Parametera CH FH Total 
Statins 24 16 40 
Fibrates 1 0 1 
Statin + Nicotinic acid 1 0 1 
Statin + Ezetimibe 4 17 21 
Statin + Fibrates 2 0 2 
Fibrates + Ezetimibe 1 0 1 
Omega 3 1 0 1 
Unknown 2 1 3 
Total (n) 36 34 70 
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Statins is the most prescribed class of drugs in both populations, as single prescription and also in 
combination with ezetimibe. Considering the fraction where they are used as single therapeutic, the 
prevalence is of 67% in the CH group, and 47% in the FH. This fraction is less expressive in the FH 
group because of a combined therapy of statins plus ezetimibe that reaches 50% of the patients. 
Simvastatin and rosuvastatin seem to be the most administered statins in both groups and in both 
types of prescriptions (single and combined), followed by atorvastatin, pravastatin and pitavastatin. 
Considering that, the data herein obtained were analysed comparing patients on treatment vs. 
patients not receiving any LLT medication (Table 3.4). 
 
Table 3.4 Lipid and lipoproteins profile: exploring the effect of disease and treatment. 
aData presented as number or Median [IQR]; *Kruskal-Wallis with Dunn’s multiple comparisons test vs 
normolipidemic; bTwo-way ANOVA with Bonferroni post test: +CH vs FH and # non-LLT vs LLT in CH.  
ApoA1: Apolipoprotein A1; CH: Clinical hypercholesterolemia; FH: Familial hypercholesterolemia; HDL: High 
density lipoprotein; LDL: Low density lipoprotein; LLT: under lipid lowering therapy; Non-LLT: not under lipid 
lowering therapy; TC: Total cholesterol 
 
CH patients have, as expected, higher levels of TC and LDL than normolipidemic patients (Kruskal-
Wallis test, p<0.001). CH non-LLT group has a significantly lower HDL concentration (Kruskal-Wallis 
test, p<0.05) and CH LLT group has higher ApoA1 levels (Kruskal-Wallis test, p<0.01). 
FH patients had also elevated TC and LDL comparatively to normolipidemics (Kruskal-Wallis, 
p<0.001) and to CH disease group (Two-way ANOVA, p<0.05), while HDL and ApoA1 levels did not 
differ. 
LLT use affected particularly HDL and ApoA1, with higher levels in the treated groups (Two-way 
ANOVA, p<0.01). 
The percentage of patients with HDL<40 mg/dL was higher in CH non-LLT patients (68%), followed 
by FH non-LLT (33%), 32% in normolipidemic, 25% in CH LLT and 18% on FH LLT. 
 
 
 
 
Parameter 
(mg/dL)a 
Normo 
lipidemia CH
 FH p valueb 
  Non-LLT LLT Non-LLT LLT  
n 65 40 36 12 34  
TC 164 [153-177] 226[212-253]*** 241[210-275]*** 234[214-261]*** 256[224-299]*** + 
LDL 92 [83-108] 154[139-173]*** 162[134-180]*** 166[149-182]*** 179[156-226]*** + 
HDL 50 [37-61] 38 [33-48]* 56 [40-67] 44 [36-47] 50 [44-57] ## 
ApoA1 138[119-165] 127[115-150] 169[139-185]** 135[119-141] 147[134-160] ### 
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3.3. Serum homocysteine levels 
 
Table 3.5 Total homocysteine levels in the studied groups. 
aData presented as Median [IQR]. CH: Clinical hypercholesterolemia; FH: Familial hypercholesterolemia; LLT: 
under lipid lowering therapy; Non-LLT: not under lipid lowering therapy; NS: Non-significative; tHcy: total 
homocysteine 
 
Serum tHcy levels did not differ among the studied groups. Furthermore, most of patients had tHcy 
levels within the normal range (5-15 µM). 
Five patients (2 Normolipidemic and 3 CH) presented moderate HHcy (16-30	µM) and two (1 CH 
and 1 FH) had intermediate HHcy (31-100 µM). On the selected population, no severe HHcy (>100	
µM) was found.  
None of the samples presented a tHcy concentration higher than the HLOQ (50 µM). 
 
The levels of fHcy varied greatly among groups, and it was not quantifiable (<0.625 µM) in 9% of 
normolipidemia condition and in about 90% of FH patients (Chi-square test, p<0.001) (Figure 3.5). 
 
 
 
 
Figure 3.5 Percentage of patients with non-quantifiable levels of free homocysteine (<0.625 
µM). Chi-square test, p<0.001. CH: Clinical Hypercholesterolemia; FH: Familial Hypercholesterolemia; LLT: 
Lipid lowering therapy; Non-LLT: Not under lipid lowering therapy 
 
 
Moreover, while the effect of therapy in FH did not influence the percentage of quantifiable fHcy, in 
CH patients the values dropped from 65% in non-LLT to 22% in LLT group. 
In the normolipidemia group, the median [IQR] value of fHcy was 1.5 [1.1-2.1] µM, which 
corresponds to 15% of tHcy and the median [IQR] value of S-Hcy-protein was 9 [7-11] µM, 85% of 
tHcy. 
Parameter (Unit)a Normolipidemia CH FH p value 
  Non-LLT LLT Non-LLT LLT  
Serum tHcy (µM) 10 [8-13] 9 [7-12] 9 [8-12] 9 [6-10] 8 [6-10] ns 
Quantifiable free Hcy fraction Non-quantifiable free Hcy fraction 
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3.4 PON1 lactonase activity 
 
Accuracy, intra and inter-assay precision data of the method were higher than 94, 93 and 92%, 
respectively, for the QCs, LLOQ and HLOQ. Calibration curves were linear (r2= 0.999 ± 0.0002) and 
there were no differences between their slopes and elevations (F-test).  
LACase results are shown in Table 3.6. 
 
Table 3.6 Lactonase activity in the study population. 
aData presented as Median [IQR]; *Kruskal-Wallis with Dunn’s multiple comparisons test vs Normolipidemic; 
bTwo-way ANOVA with Bonferroni post test: +CH vs FH and # non-LLT vs LLT in CH.  
ApoA1: Apolipoproteina A1; CH: Clinical hypercholesterolemia; FH: Familial hypercholesterolemia; HDL: High 
density lipoprotein; LACase: Lactonase; LLT: under lipid lowering therapy; Non-LLT: not under lipid lowering 
therapy; NS: Non-significative; tHcy: total homocysteine 
 
Regarding the LACase activity, the FH group had a lower activity than CH patients (Two-way 
ANOVA, p<0.001) (Table 3.7).  
CH non-LLT patients had higher LACase/HDL and LACase/ApoA1 ratios than normolipidemic 
patients (Kruskal-Wallis, p<0.01) and presented differences in both ratios towards the treated CH 
group (Two-way ANOVA, p<0.05).  
Also, FH patients had lower ratios than CH, regardless of therapy (Two-way ANOVA, p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter 
(Unit)a 
Normo 
lipidemia CH FH 
p 
valueb 
  Non-LLT LLT Non-LLT LLT  
LACase 
(kU/L) 8 [5-10] 10 [8-12]
 10 [8-12] 5 [4-7] 7 [3-9] +++ 
LACase/ 
tHcy 0.9[0.5-1.2] 1.1 [0.8-1.3] 1.0 [0.7-1.4] 0.6 [0.4-1.2] 0.7 [0.5-1.2] ns 
LACase/ 
HDL 0.15[0.11-0.19] 0.22[0.16-0.33]
** 0.18[0.12-0.24] 0.11[0.09-0.17] 0.13[0.06-0.19] 
+++ 
# 
LACase/ 
ApoA1 0.05[0.04-0.07] 0.07[0.05-0.10]
* 0.06[0.04-0.08] 0.04[0.03-0.05] 0.04[0.02-0.06] 
+++ 
# 
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4. DISCUSSION 
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In the present work, the differences in plasma fractions of Hcy among normolipidemic and 
hypercholesterolemic patients – CH vs FH - were explored by using serum samples from a national 
survey for the study of cardiovascular disease in Portugal (eCOR and FH Portuguese study). In this 
regard, an HPLC-FD method for the tHcy and fHcy quantification was optimized and validated.  
Most patients had normal tHcy levels and the tHcy concentration was similar among the three 
study groups. A decrease in the fHcy fraction in hypercholesterolemic populations was found, which 
was particularly evident in FH, suggesting an increased S-homocysteinylation of proteins in this 
population.  
Susceptibility to N-homocysteinylation of plasmatic proteins is plausibly also higher in FH 
population, due to the decreased LACase activity observed, despite normal HDL and ApoA1 levels 
and regardless of lipid lowering therapy use. This evidence is also indicative that, while HDL quantity 
is not diminished in this population, its antioxidant and anti-inflammatory function might be 
compromised.  
The data presented herein points towards a higher protein targeting by Hcy in FH as well as the 
presence of dysfunctional HDL and suggest a role for protein homocysteinylation in 
hypercholesterolemia pathobiology. 
 
The method developed by Nolin and colleagues (2007) and adapted at the Translational 
Pharmacology lab, used an initial volume of sample of 100 µL. However, in multi-parameter 
measurement studies, the volume of sample available becomes a limiting step and is imperative to 
use the least possible volume. So, by necessity of magnifying the volume of sample available for 
future use, an attempt was made to apply the less volume of biological fluid possible. The reduction 
was first tested on standards with the initial volume set to 50 µL and half the volumes applied in 
Nolin’s method, for all reagents. The reduction in sample volume represents an advantage of the 
optimized method. 
Although not being very cost-effective relatively to the reagents used, volumes of reagents are in 
the range of few µL and the HPLC device allows a daily quantification of 50 samples (plus 10 
standards and 10 blank samples). It is also a relatively simple method with high reproducibility and a 
short run time for each sample (20 min). High accuracy, inter-assay precision and stability of solutions 
assured the validation of the method. 
Besides Hcy, four more aminothiols were simultaneously quantified for the 187 samples (Cys, Cys-
Gly, GSH and NAC), whose results are not presented herein but represent future work considering the 
interconversion that exists among these aminothiols and that confers relevance to a simultaneous 
quantification.  
The range of Hcy standard concentrations (0.625 µM to 50 µM) was set according to normal 
human plasma concentrations detected in different studies. Normal tHcy ranges from 5 to 15 µM and 
intermediate to severe HHcy conditions (>31 µM) are rare (Hankey and Eikelboom, 1999; Jakubowski, 
2008). In populations with known tendency for HHcy such as chronic kidney disease (Zinellu et al., 
2010), higher standard concentrations should be considered. However, to the present study it was not 
necessary and the method demonstrates a good sensitivity towards tHcy quantification.  
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Considering that 20 to 30% of tHcy circulates in its free oxidized form (homodimers and mixed 
disufides) a concentration of free oxidized Hcy ranging from 1 to 4.5 µM is expected in circulation 
(Hankey and Eikelboom, 1999; Jakubowski, 2006; Mudd et al., 2000). The free reduced Hcy fraction, 
however, is much lower, around 0.1 µM (Jakubowski, 2006) and this could explain the lack of 
sensitivity to assess the lower concentrations of fHcy present in the hypercholesterolemic populations. 
Thus, further effort should be put into achieving a LLOQ more adequate to that kind of concentrations.  
 
This method was applied to a cohort of normolipidemic subjects and two hypercholesterolemic 
populations with genetic and non-genetic background. The study groups were homogenous regarding 
sex and age of individuals but differed greatly in the percentage of patients under lipid lowering 
therapy, the highest proportion of treated patients resided at the FH population. More than 70% were 
under treatment in the FH group. This proportion diminished to approximately 50% in the clinical 
dyslipidemia.  
Statins are one of the most prescribed drug classes nowadays, not only as single medication but 
also in a combined form with other drugs and this is reflected also in the hypercholesterolemic 
populations of this study. Statins inhibit cellular cholesterol synthesis and are widely used to reduce 
LDL in persons with high levels of this lipoprotein and cardiovascular risk (Mackness and Mackness, 
2015). Their target is the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase 
(Avis et al., 2007), the enzyme that catalyzes the step of HMG-CoA conversion to mevalonate in the 
cholesterol synthesis pathway and the rate-limiting step of the process (Avis et al., 2007). Unlike 
general dyslipidemias, it is difficult to treat FH with only dietary habits, physical activity and statin 
medication. In some cases, a combined therapy of statins with other drugs may be needed to achieve 
the target levels (Marks et al., 2003). In FH group, a combination of statins and ezetimibe was applied 
in a greater number of persons than statins only, and that is explained by the fact that LDL levels are 
more difficult to lower in these patients because of the genetic cause associated that implicates higher 
LDL levels in circulation than a clinical dyslipidemia. A combined therapy of statins and ezetimibe may 
reduce LDL levels in 10 to 20% more than a single statin therapy (Kim and Han, 2013) and that is due 
to ezetimibe mechanism of action that suppresses dietary and biliary cholesterol absorption on the 
intestine, lowering the income to the liver (Kim and Han, 2013; Marks et al., 2003).  
Although the groups were divided according to their TC levels, when analysing Table 3.4, it could 
be observed that, at least in CH and FH groups, TC levels were mostly influenced by raised LDL 
levels, as opposite to HDL levels that were similar to normolipidemics with exception of non-LLT CH 
that had a median value lower than the recommended. ApoA1, the apolipoprotein associated with 
HDL also presented similar values to the normolipidemia condition. In the treatment groups, HDL 
concentration is restored to normal levels (>40 mg/dL) and ApoA1 even surpasses the levels of 
normolipidemia condition and remains above the recommended levels (>120 mg/dL – ESC/EAS, 
2011). Some hypothesis could explain this raise in HDL and ApoA1 levels. Avis and colleagues 
reported a “mild but significant elevation” of HDL and ApoA1 levels (3.6 and 2.4%, respectively) based 
on a pooled data of six studies of statin therapy in FH children (Avis et al., 2007). Three of those 
studies showed a significant increase for both HDL and ApoA1 after atorvastatin 20 mg (4.6 and 1.9%, 
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respectively), simvastatin 40 mg (4.7 and 4.8%) and pravastatin 40 mg treatment (9.4 and 5.1%), all of 
which were also prescribed to CH and FH patients in this study (see Avis et al., 2007). Statins effect 
on HDL, however, is not unanimous. They are widely prescribed to lower LDL and TC since there are 
other compounds more suitable when the goal is to raise HDL levels. The drugs of choice for the 
treatment of hypertriglyceridemia and low HDL are fibrates (fibric acid synthetic derivatives), n3-fatty 
acids (eg. omega 3), nicotinic acid, or derivatives from this compound, which act primarily on the 
adipocytes (Dierkes et al, 2007). Despite the use of fibrates in four CH patients, omega 3 and nicotinic 
acid also in one each, these frequencies would probably not influence HDL and ApoA1 levels in CH. 
Besides, in FH group these were not prescribed drugs. The fact that ezetimibe reduces cholesterol 
absorption from the intestine to the liver influencing hepatic storage and raising cholesterol clearance 
from the blood, might be an explanation for higher HDL levels. At least two studies involving FH 
subjects detected a significant raise in HDL and ApoA1 concentration after ezetimibe treatment only 
(Dujovne et al., 2002) and a combined treatment with statin (Gagné et al, 2002).  
 
THcy differences among groups were not perceptible, and HHcy was not significant in the study 
population (only 7 patients presented moderate to intermediate HHcy). Every increase of 2.5 µM in 
plasma Hcy may be associated with an increase of stroke risk of about 20%.  
Although HHcy is a context of concerning, Hcy levels below that mark can also be damaging. For 
instance, a plasma Hcy concentration of 11 µM is able to inhibit tissue plasminogen activator (t-PA) 
binding to annexin II (its major endothelial cell receptor) by 50%, a critical loss of fibrinolytic potential 
and an important factor in the aetiology of vascular disorders (Malinowska et al., 2012).  
When considering N-homocysteinylation, hyperhomocysteinemic concentrations (>15 µM) in the 
blood are required to favour the HcyTL formation and its reaction with Lys residues of proteins 
(Yilmaz, 2012). Despite that, when Hcy enters HcyTL pathway, only 10 nM of HcyTL are required to 
start the acylation of amino residues (Jakubowski, 2008), a concentration quite inferior to the ones 
required for S-homocysteinylation, corroborating the theory that this metabolite is more reactive and 
toxic than the Hcy thiol itself and more proatherogenic (Yilmaz, 2012). 
Even at acceptable tHcy concentrations, a sharp difference among hypercholesterolemia groups 
when considering Hcy fractions was herein found. There is a very clear loss of fHcy fraction towards 
the hypercholesterolemic groups, and this is even more evident in the FH population where only one 
subject from the non-LLT and three from the LLT had fHcy above the LLOQ (0.625 µM).  
Therefore, the FH population is particularly prone to protein targeting by S-homocysteinylation. In 
fact, in 1991, Olszewski and McCully had already found that all lipoprotein fractions of 
hypercholesterolemic subjects contained a considerably higher level of Hcy as opposed to 
normolipidemic ones, with the largest difference seen in the LDL fraction (Olszewski and McCully, 
1991). Hcy incorporation creates altered proteins with newly acquired interactions that can change 
their structure and be detrimental to the organism (Jakubowski, 2008). It can have several 
consequences, depending on the protein homocysteinylated. For example, S-homocysteinylation of 
ApoB, a major component of LDL, leads to an increased production of reactive oxygen species (ROS) 
and cytotoxicity (Jakubowski, 2013).  
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PON1 has unique characteristics not only protecting LDL and HDL against oxidation, but also its 
anti-inflammatory and anti-thrombotic functions that are manifested through its different catalytic 
activities. Interestingly, PON1 has a single free sulfhydryl group at position 284 constituted by a Cys. 
Cys284 is associated with the enzyme’s activity, although it is not part of the active site (Tavori et al., 
2010). In 1998, Aviram and co-workers suggested that Cys284 participates in LDL oxidation 
detoxification (Aviram et al., 1998). Thus, PON1 free Cys residue in position 284 might be a target for 
S-homocysteinylation, with consequent inactivation of its antioxidant capacity of protecting LDL 
against oxidation (Figure 4.1).  
 
 
 
 
 
 
 
 
 
Figure 4.1 Hypothesis of paraoxonase-1 as a target for homocysteine and a plausible 
explanation for the loss of activity in familial hypercholesterolemia. Cys284: Cysteine residue in 
position 284; Hcy: Homocysteine; PON1: Paraoxonase-1; LDL: Low-density lipoprotein; ox-LDL: Oxidized low-
density lipoprotein. 
  
Dierkes and colleagues did an extensive review about lipid lowering drugs effects on Hcy levels 
(Dierkes et al., 2007). With respect to statins, the few studies made, came to the same conclusion: 
they do not influence Hcy levels substantially. A one year long prospective study with lovastatin 
resulted in a small Hcy reduction and another with concurrent supplementation of vitamins and statins 
had the same degree of reduction in both groups, revealing the lack of relevance of the statin 
component. 
As to fibrates, numerous short and long-term studies on fenofibrate and other fibric acid derivatives 
revealed an elevation of Hcy from 40 to 50% (see Dierkes et al., 2007). This review enclosed also 
nicotinic acid and n3-fatty acids, both giving less clear responses of their action over Hcy. 
Unfortunately, there are no studies concerning the effects of LLT on the free and protein-bound 
fractions of Hcy. Plausibly, S-Hcy-protein targeted therapeutic would have a role in 
hypercholesterolemia treatment.  
 
 
35 
 
The assessment of LACase activity existent in PON1 enzyme, using a method previously 
developed and validated at Translational Pharmacology lab (Dias et al., submitted) revealed 
significant differences between disease groups (p<0.001). 
Currently, it is known that HDL functionality is a far better indicator of its ability to protect against 
atherogenesis than its concentration levels (Mackness and Mackness, 2013). This concept first arose 
from observations that some individuals with high or normal HDL were more susceptible to CHD 
development if they had low PON1 activity than others with high PON1 activity even if HDL 
concentration was low (Navab et al., 1997). 
The FH population showed a normal HDL and ApoA1 concentration that was slightly improved by 
LLT but in opposite had decreased LACase activity. The LACase/HDL and LACase/apoA1 ratios 
corroborate the presence of equal quantity of HDL but dysfunctional performance regarding LACase 
activity.  
Considering the importance of this enzyme to detoxify HcyTL deleterious action in the organism 
and other endogenous lactones, specifically its pro-thrombotic and pro-inflammatory effects and the 
fact that this population has, by default, atherogenic factors in circulation, leads to the observation of a 
very sensitive and unprotected group of subjects, as documented by Ferretti and co-workers who 
observed that an HDL with low PON1 activity is more susceptible to homocysteinylation than an HDL 
with high PON1 activity (Ferretti et al., 2003).  
Not only is this population more susceptible to S-homocysteinylation of proteins, as was concluded 
before, but is also clearly unprotected towards N-homocysteinylation. N-Hcy-proteins elicit an 
autoimmune response in humans that is enhanced in cardiovascular disease patients (Jakubowski, 
2006). Unlike tHcy, HcyTL is effectively eliminated in the urine. HcyTL concentrations in the urine (11-
485 nM) are around 14 times greater than plasma HcyTL levels (0-35 nM) (Jakubowski, 2006). Urinary 
excretion is consistent with the hypothesis of HcyTL being a toxic metabolite in the organism. 
Several research groups have been dedicated to evaluate statins effect on PON1 activity, 
specifically the two most studied, paraoxonase (POase) and arylesterease (AREase) activities. 
However, to our knowledge, there are no studies indicating the effect they would have on LACase 
activity. In the future, it would be pertinent to understand what kind of effect, if any, they have on this 
activity of PON1, in a wider population. 
 
The data herein obtained supports that the pathophysiological role of Hcy on hypercholesterolemia 
may reside in its ability to post-translationally modify tissue proteins through S or N-
homocysteinylation at acceptable tHcy concentrations. It also emphasizes the limited value of tHcy 
concentration by itself.  
In the future, it will be interesting to identify which target proteins are modified and thus involved in 
vascular pathology onset and progression. Also, the data herein obtained show that protein molecular 
targeting by Hcy differs among clinical and familial hypercholesterolemic conditions, giving future 
perspectives for its use as biomarkers to predict risks and to guide therapeutic decisions. 
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Adding to these selected 187 subjects, 1106 individuals from four regions of the eCOR study have 
all three PON1 activities quantified: LACase, POase and AREase. Both POase and AREase protocols 
are very similar to the one described in this thesis, with a very small volume of sample required to do a 
colorimetric assay. Briefly, POase is the activity that metabolises paraoxon, the toxic metabolite of the 
insecticide parathion that has a potent acetylcholinesterase inhibition effect on animals and humans 
(Kim et al., 2013). The AREase activity facilitates the detoxification of aromatic esters, being phenyl 
acetate one of its best substrates (Draganov et al., 2005). All three activities have characteristics that 
confer PON1 a significant relevance in HDL’s antioxidant effects on the organism. 
In order to fully validate the accuracy and utility of these biomarkers, the future work comprises the 
quantification of all Hcy fractions in the remaining subjects and the correlation of those values with 
PON1 activity results and clinical data.  
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Annex 1. Familial hypercholesterolemia diagnostic criteria based on Simon Broome Heart 
Research Trust (adapted from Bourbon and Rato, 2006). 
 
 
Possible Familial 
Hypercholesterolemia Confirmed Familial Hypercholesterolemia 
Children 
under 
16 
TC>200 
mg/dL or 
LDL>120 
mg/dL 
 
• Family history of 
myocardial infarction 
before the age of 50 in 
grandparents, aunts or 
uncles or before the age of 
60 in parents, siblings or 
children 
• Family history of 
hypercholesterolemia 
TC>200 
mg/dL or 
LDL>120 
mg/dL 
• Tendon xanthoma in the index 
case or relative 
• Genetic evidence of a mutation 
in the LDL receptor gene or 
APOB 
• Family history of 
hypercholesterolemia Adults 
TC>290 
mg/dL or 
LDL>190 
mg/dL 
TC>290 
mg/dL or 
LDL>190 
mg/dL 
 
 
 
 
